Q&A: Dr Dan Bloomfield Elaborates on Novel Findings From AZALEA-TIMI 71 Trial, Future of FXI Inhibitor Abelacimab
The AZALE-TIMI 71 study was designed to investigate the efficacy of abelacimab, an investigational, fully human monoclonal antibody that closely binds with factor XI (FXI), versus rivaroxaban to reduce bleeding risks in patients with atrial fibrillation. …